-
Innovation Ranking
NewInnovation Ranking – Editas Medicine Inc
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics,...
-
Product Insights
NewNet Present Value Model: Editas Medicine Inc’s Renizgamglogene Autogedtemcel
Empower your strategies with our Net Present Value Model: Editas Medicine Inc's Renizgamglogene Autogedtemcel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Editas Medicine Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Editas Medicine Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Net Present Value Model: Editas Medicine Inc’s EDIT-301
Empower your strategies with our Net Present Value Model: Editas Medicine Inc's EDIT-301 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Bristol-Myers Squibb Co’s Farletuzumab Ecteribulin
Empower your strategies with our Net Present Value Model: Bristol-Myers Squibb Co's Farletuzumab Ecteribulin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Renizgamglogene Autogedtemcel in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Renizgamglogene Autogedtemcel in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Renizgamglogene Autogedtemcel in Sickle Cell Disease Drug Details: EDIT-301...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadravaleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadravaleucel in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadravaleucel in Relapsed Multiple Myeloma Drug Details: GDA-201 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadravaleucel in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadravaleucel in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadravaleucel in Refractory Multiple Myeloma Drug Details: GDA-201 is under development...
-
Product Insights
Hemoglobinopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinopathies - Drugs In Development, 2023’, provides an overview of the Hemoglobinopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Herpetic Keratitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Herpetic Keratitis - Drugs In Development, 2023’, provides an overview of the Herpetic Keratitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpetic Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...